Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mika Komori

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Brain and Nerve = Shinkei Kenkyu No Shinpo|June 12, 2009
[Mitoxantrone for the treatment of patients with multiple sclerosis]Mika Komori, Takayuki Kondo, Masami Tanaka
European Neurology|July 11, 2009
Interferon-beta(1b) treatment in neuromyelitis opticaMasami Tanaka, Keiko Tanaka, Mika Komori
Rinsho Shinkeigaku = Clinical Neurology|April 17, 2007
[Treatment]Takahiko Saida, Masami Tanaka, Mika Komori, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 21, 2007
Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibodyMasami Tanaka, Keiko Tanaka, Mika Komori, et al.
Expert Opinion on Drug Safety|June 24, 2022
Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trialYoichiro Hashimoto, Mika Komori, Yuka Tanji, et al.
Journal of Pain Research|May 31, 2023
Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU StudyShigekazu Kitamura, Noboru Imai, Yuka Tanji, et al.
Neurology and Therapy|September 22, 2022
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled TrialYasuhiko Matsumori, Mika Komori, Yuka Tanji, et al.
Advances in Therapy|September 22, 2022
Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU TrialTakao Takeshima, Mika Komori, Yuka Tanji, et al.
Frontiers in Neuroscience|April 16, 2021
Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory ActivityRuturaj Masvekar, Jonathan Phillips, Mika Komori, et al.
Plos One|December 11, 2012
Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammationBibiana Bielekova, Mika Komori, Quangang Xu, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Brain and Nerve = Shinkei Kenkyu No Shinpo|June 12, 2009
[Mitoxantrone for the treatment of patients with multiple sclerosis]Mika Komori, Takayuki Kondo, Masami Tanaka
European Neurology|July 11, 2009
Interferon-beta(1b) treatment in neuromyelitis opticaMasami Tanaka, Keiko Tanaka, Mika Komori
Rinsho Shinkeigaku = Clinical Neurology|April 17, 2007
[Treatment]Takahiko Saida, Masami Tanaka, Mika Komori, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|August 21, 2007
Anti-aquaporin 4 antibody in Japanese multiple sclerosis: the presence of optic spinal multiple sclerosis without long spinal cord lesions and anti-aquaporin 4 antibodyMasami Tanaka, Keiko Tanaka, Mika Komori, et al.
Expert Opinion on Drug Safety|June 24, 2022
Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trialYoichiro Hashimoto, Mika Komori, Yuka Tanji, et al.
Journal of Pain Research|May 31, 2023
Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU StudyShigekazu Kitamura, Noboru Imai, Yuka Tanji, et al.
Neurology and Therapy|September 22, 2022
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled TrialYasuhiko Matsumori, Mika Komori, Yuka Tanji, et al.
Advances in Therapy|September 22, 2022
Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU TrialTakao Takeshima, Mika Komori, Yuka Tanji, et al.
Frontiers in Neuroscience|April 16, 2021
Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory ActivityRuturaj Masvekar, Jonathan Phillips, Mika Komori, et al.
Plos One|December 11, 2012
Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammationBibiana Bielekova, Mika Komori, Quangang Xu, et al.
Pageof 6